Institute for Cardiovascular Research， University of Leeds， UK.
BACKGROUND: After acute myocardial infarction (AMI)， patients with a history of arterial hypertension (AH) have a worse prognosis than normotensives. Whether this adverse risk is beneficially modulated by treatment with angiotensin-converting enzyme (ACE) inhibitors is unknown. We evaluated the prognostic value of antecedent hypertension in post-AMI patients given ACE inhibitor therapy.
METHODS: We analysed retrospectively data from the AIRE study (randomised， placebo-controlled trial of ramipril in 2006 post-AMI patients with clinical heart failure). A history of AH was present in 28% of the patients. We examined the prognostic value of antecedent hypertension separately among placebo and ramipril treated patients and also the effect of ramipril on clinical outcomes according to whether or not a history of AH was present.
RESULTS: Antecedent hypertension was a significant indicator of adverse prognosis in the placebo (P) treated patients (Hazard Ratio 1.49， 95% Confidence Intervals 1.13 to 1.97， P = 0.005) but not in the ramipril (R) treated patients (1.17， 0.84 to 1.61， P = 0.34). A similar pattern was observed for the risks of sudden death (P: 1.75， 1.21 to 2.54， P = 0.003; R: 1.34， 0.86 to 2.07， P = 0.18) and severe/resistant heart failure (P: 1.48， 1.08 to 2.03， P = 0.014; R: 1.18， 0.83 to 1.68， P = 0.37). Treatment with ramipril reduced the all-cause mortality risk in both hypertensive (0.63， 0.44 to 0.89， P = 0.009) and normotensive patients (0.78， 0.61 to 0.99， P = 0.041).
CONCLUSION: Antecedent hypertension is not a significant prognosticator in patients with AMI and clinical heart failure given ACE inhibitor therapy